This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6fzr
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of scFv-SM3 in complex with compound 2== | |
| - | + | <StructureSection load='6fzr' size='340' side='right'caption='[[6fzr]], [[Resolution|resolution]] 1.80Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6fzr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FZR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FZR FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EEQ:2-fluoranyl-~{N}-[(2~{S},3~{R},4~{R},5~{R},6~{R})-6-(hydroxymethyl)-2,4,5-tris(oxidanyl)oxan-3-yl]ethanamide'>EEQ</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fzr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fzr OCA], [http://pdbe.org/6fzr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fzr RCSB], [http://www.ebi.ac.uk/pdbsum/6fzr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fzr ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] Note=MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence (PubMed:20816948). Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref> The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Lk3 transgenic mice]] | ||
| + | [[Category: Asensio, J L]] | ||
| + | [[Category: Avenoza, A]] | ||
| + | [[Category: Bermejo, I A]] | ||
| + | [[Category: Busto, J H]] | ||
[[Category: Castro-Lopez, J]] | [[Category: Castro-Lopez, J]] | ||
| - | [[Category: | + | [[Category: Cocinero, E J]] |
| - | [[Category: | + | [[Category: Companon, I]] |
| - | [[Category: | + | [[Category: Corzana, F]] |
| - | [[Category: | + | [[Category: Fernandez, J A]] |
| - | + | ||
| - | + | ||
[[Category: Hurtado-Guerrero, R]] | [[Category: Hurtado-Guerrero, R]] | ||
[[Category: Insausti, A]] | [[Category: Insausti, A]] | ||
| + | [[Category: Jimenez-Barbero, J]] | ||
| + | [[Category: Jimenez-Oses, G]] | ||
| + | [[Category: Peregrina, J M]] | ||
[[Category: Usabiaga, I]] | [[Category: Usabiaga, I]] | ||
| - | [[Category: | + | [[Category: Immune system]] |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Crystal structure of scFv-SM3 in complex with compound 2
| |||||||||||
Categories: Large Structures | Lk3 transgenic mice | Asensio, J L | Avenoza, A | Bermejo, I A | Busto, J H | Castro-Lopez, J | Cocinero, E J | Companon, I | Corzana, F | Fernandez, J A | Hurtado-Guerrero, R | Insausti, A | Jimenez-Barbero, J | Jimenez-Oses, G | Peregrina, J M | Usabiaga, I | Immune system
